multidisciplinary treatment of selected patients with advanced or metastatic GIST following TKI therapy. However, the benefit of surgical resection in these patients with intra-abdominal metastatic/ recurrent GIST following tyrosine kinase inhibitor (TKI) therapy remains unclear and randomized control trials to answer this question have been unsuccessful due to early closure for to poor accrual. 5 Over the last 15 years, a number of retrospective studies have evaluated the role of surgery in the multidisciplinary management of patients with metastatic GIST and identified prognostic factors associated with survival. 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In these reports, patients with progressive disease on TKI therapy did poorly. Interpretation of the outcomes of these studies is challenging because the majority of the studies included patients that underwent not only R0 or R1 resection, but also those patients who treated with palliative resection (R2 resection-not all gross disease resected). [6] [7] [8] [9] [10] [11] [12] [13] [14] [16] [17] [18] In addition, the majority of studies examined both preoperative and postoperative factors associated with outcomes, making it difficult to identify which patients benefited most from surgical resection.
The aim of this study was to identify preoperative factors in patients that underwent macroscopically compete surgical resection (R0/R1) of metastatic or recurrent GIST that were associated with poor oncologic outcomes, with the goal of identifying which patients were unlikely to benefit from the inclusion of surgical resection in their multidisciplinary treatment plan. Complete macroscopic resection was achieved in 87 patients and were included in the analytic cohort. A clinical database was constructed including patient, tumor, treatment, and outcome data. Clinicopathologic variables included: age at diagnosis, initial presentation (primary/ metastatic; primary tumor location), duration of TKI therapy prior to surgery, overall duration of TKI therapy, radiographic response to TKI therapy (patients were classified as having progression when either a new lesion occurred or an increase in size was observed. This includes patients with less than 20% increase in size as per RECIST), and disease extent at the time of surgery (which was defined using two parameters:
| PATIENTS AND METHODS
focality and number of sites). Focality was defined as the number of tumors within the same organ/cavity (ie, number of nodules in the peritoneum or liver). Number of sites is defined as single site (ie, peritoneum only) versus multisite (ie, liver and peritoneum, etc). A subset of patients (n = 15) underwent surgical resection of metastatic disease and had residual "treated" liver metastases that remained in situ, as evidenced by cystic change with a presumed complete radiographic response and considered controlled at the time of surgery with no further intervention planned.
| Statistical methods
For overall survival, an event was defined as the time from surgical resection to death due to any cause. For GIST-specific survival, an event was defined as (A) the time from surgical resection to death due to GIST and (B) the time from TKI initiation to death due to GIST. For time to recurrence, the time from surgical resection to recurrence (local or distant-which ever came first) was defined as an event. Univariate survival estimates for overall survival, GIST-specific survival, and time to recurrence were calculated using Kaplan-Meier curves and significance was assessed using the log-rank test. Three percent of patients in the study died during follow-up from non-GIST related causes. Therefore, a multivariable competing risk regression analysis was used to determine the subdistribution hazard ratios (HRs). Factors included in the multivariate model include were those felt to be of clinical (age) and statistical importance (P < 0.1 by univariate analysis).
Death due to causes other than GIST were taken into account as competing events in all analyses except for overall survival.
| RESULTS
One-hundred seven patients with metastatic/recurrent GIST who were treated with TKIs and surgical resection were identified. Of these, 17 patients underwent palliative resection only and three patients were treated with TKI for less than 30 days and were excluded. Complete macroscopic resection was achieved in 87 patients which comprise the analytic cohort for this study ( Table 1 ).
The median age at the time of initial diagnosis was 55 years and 54% were male. Primary tumors were most often located in the stomach (n = 33, 38%) or small bowel (n = 28, 32%). At the time of initial diagnosis, 53 patients (61%) had localized disease. Prior to presentation to our institution, 19 of these patients had the primary tumor resected at the time of initial diagnosis and had metastatic disease left in situ. Overall, 34 patients (39%) had metastatic disease at the time of initial diagnosis, while 43 (50%) developed metachronous metastatic disease at a median of 36 months following primary resection. A total of 10 patients developed a local recurrence at a median of 37 months.
| Clinicopathologic characteristics at the time of surgical resection for recurrent or metastatic intra-abdominal GIST
Prior to surgical resection of recurrent or metastatic disease, the median duration of neoadjuvant TKI was 667 days. All patients except one were treated with imatinib preoperatively. A total of 25 patients (29%) were switched to another TKI due to progression prior to surgery. A total of 91% (n = 79) of patients continued TKI therapy after surgery. A total of 44 patients (51%) had a single site of disease and 49% of patients had multisite disease ( Table 1) . The majority of patients had multifocal disease (n = 63, 72%). Radiographically, 22 patients (25%) had evidence of tumor regression and 9 (10%) had stable disease/"no progression." An additional 36 (41%) patients had evidence of regression followed by tumor progression prior to surgical resection and 20% of patients had progressive disease throughout treatment. These two groups were categorized as "any progression." Univariate analyses for preoperative factors associated with TTR and GIST-specific survival from the time of surgery (Table 2) as well as GIST-specific survival from the time of TKI initiation (Supplementary Table S1 ) were performed. Unifocal/single site disease at time of resection, duration of TKI < 365 days, and no evidence of radiographic progression were associated with improved TTR and DSS. Fifty-three percent (n = 46) of patients had mutation status available. We did not find an association between mutational status and outcomes in this cohort (data not shown).
| Cancer-related outcomes
By multivariable analyses (Table 3 , Figure 1 , Supplementary   Table S2) , patients with evidence of radiographic tumor progression prior to surgical resection had a significantly worse GIST-specific to imatinib treatment had significantly longer progression-free survival and overall survival compared to imatinib alone. The authors concluded that surgical resection of residual lesions is likely to be beneficial to patients with recurrent or metastatic GIST. Data such as these have led to the inclusion of surgery in the National
Comprehensive Cancer Network guidelines as part of the treatment algorithm for patients with recurrent of metastatic GIST. 22 The guidelines suggest that patients with a favorable response or those with limited progression may be considered for surgical resection.
Furthermore, future randomized trials are unlikely to be undertaken given the lack of clinical equipoise. Therefore, additional studies on existing data to determine which subset of patients with metastatic
GIST are most likely to benefit are critical.
There is significant heterogeneity among patients with metastatic GIST and identifying preoperative factors associated with improved outcomes is challenging. To date, the inability to undergo a macroscopically complete resection or resection of only progressing tumors have been consistently shown to be associated with poor outcomes. 4, 6, 7, 17, 18 In the current study, only patients that successfully underwent macroscopically complete resection were included, which reflects our current clinical practice as <15% of patients that had surgery for metastatic GIST had palliative resections and were excluded from analysis.
Previous retrospective data of patients that have undergone surgery for metastatic GIST have demonstrated that patients with stable or responsive disease appear to benefit more than patients with progressive disease. 7, 13, 14, 17 However, these studies incorporated both preoperative and postoperative factors into the multivariate modeling. Preoperatively, when clinicians are attempting to decide which patients with metastatic GIST could potentially benefit from surgery, they are not able to accurately predict whether the patent will have a surgical complication or the mitotic rate of the residual disease. In the current study, evaluation of preoperative factors alone demonstrated that radiographic progression was associated with poor outcomes with a median time to recurrence of 7.8 months and median GIST-specific survival of 35 months after surgery.
However, how the TTR and DSS in this group of patients compares to those treated with TKI alone is unknown. Data from the Phase II USFinland B222 study which was the first phase II study to evaluate imatinib in patients with metastatic GIST, sheds some light on this question.
[23] At a median follow-up of 63 months, the median OS was 57 months with a median progression-free survival of 24 months. As expected, OS was related to response, in which patients with initial progression on imatinib had a median OS of 8 months compared to 63 months for patients that had a partial response, demonstrating the poor biology of patients that are unable to achieve a response with imaitnib. In the current study, the median time from surgery to recurrence was 8 months for patients with progressive disease with an associated median survival of 35 months.
Although patients in the current study that had surgery have better outcomes than this historical control, it should be noted that the patients in the current study represent a highly selected cohort of patients that had demonstrated a more favorable biology than most patients with metastatic GIST, making it difficult to compare. The data presented in this study suggest that although patients with progressive GIST may potentially benefit from surgical resection, the benefit is likely much smaller than for those with a response to TKI and the risks and potential morbidity of resection should be carefully weighed against the theoretic benefit before proceeding. Patients with unifocal disease faired far better than patients with multifocal disease, regardless of whether their disease was in a single cavity or in multiple sites. In addition, we found that the duration of TKI therapy was not associated with outcomes when controlling for other factors such as radiographic response and extent of disease.
These data should be evaluated in the context of their limitations.
First, this was a small, non-randomized, retrospective cohort study of selected patients treated at a single institution. Despite this, we believe the data presented in this manuscript provides insight pertaining to an unanswered clinical decision-making dilemma. Inherent to the nature of retrospective studies, these data are subjective to selection bias and represent a highly selected cohort that cannot be generalized to all patients with metastatic GIST. However, the inclusion of only patients that had a macroscopically complete resection at a single institution brings uniformity in the pathologic review and treatment planning but is associated with selection bias.
| CONCLUSIONS
In 
